Clinical trials · Ohio
T-cell Lymphoma clinical trials in Ohio
We’re tracking 41 recruiting t-cell lymphoma studies with a site in Ohio — including Phase 1, Phase 1/Phase 2, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in Ohio
- NCT05633615RecruitingPhase 2
Testing new drug options after CAR T for aggressive lymphoma
This Phase 2 study tests whether adding or switching drug treatments after CAR T-cell therapy can improve outcomes for people with certain aggressive lymphomas that have come back or did not respond. It mainly looks at who remains disease-stable/partly improved after CAR T and what treatment approach works best next.
Cleveland, OhioAges 18 years+ - NCT07676877RecruitingPhase 1
Low-dose radiation before CAR-T therapy for large B-cell lymphoma
This trial adds a small, whole-body dose of radiation to the standard preparation before CAR-T cell therapy (tisagenlecleucel). The goal is to improve the treatment's effectiveness for patients with relapsed or refractory large B-cell lymphoma.
Columbus, OhioAges 18 years+ - NCT07648264RecruitingPhase 3
Immune Boost Treatment After CAR-T or TCE Therapy
This study tests a new immunoglobulin (antibody) treatment called IgPro20 in adults whose immune systems became weakened after receiving CAR-T cell or TCE therapies for blood cancers. The goal is to help strengthen your immune system and reduce infection risk.
Cincinnati, OhioAges 18 years+ - NCT05476770RecruitingPhase 1
Tagraxofusp for children with CD123-positive leukemia
This study tests tagraxofusp, a medicine that targets a marker called CD123 on cancer cells, in children and young adults whose leukemia or lymphoma has come back or is resistant to treatment. It may help by shrinking the cancer and improving disease control after standard therapies have not worked.
Cleveland, OhioAges 1–21 - NCT07356245RecruitingPhase 2
Ruxolitinib after stem cell transplant for T-cell lymphoma
This trial tests whether taking ruxolitinib after a stem cell transplant can help prevent T-cell lymphoma from coming back. It is for patients whose lymphoma is in remission (partial or complete) after their transplant.
Columbus, OhioAges 18 years+ - NCT07192471RecruitingPhase 1
Study of KK2223 for T-cell lymphoma after prior treatments
This study tests a new drug called KK2223 for people with certain types of T-cell lymphoma (PTCL or CTCL) that have not responded to previous treatments. The goal is to find out if the drug is safe and if it helps shrink or control the lymphoma.
Cleveland, OhioAges 18 years+ - NCT07188558RecruitingPhase 3
Comparing ronde-cel to standard CAR T-cell therapy for large B-cell lymphoma
This trial tests a new treatment called ronde-cel against the usual CAR T-cell therapy for people with large B-cell lymphoma that has come back or not responded to initial treatment. The goal is to see if ronde-cel works better.
Cincinnati, OhioAges 18 years+ - NCT07101328RecruitingPhase 1
Study of LY4152199 for Lymphoma That Returned or Didn't Respond
This study tests a new medicine called LY4152199 for people with certain types of lymphoma (follicular or diffuse large B-cell) that came back or didn't respond to previous treatment. The goal is to see if the drug is safe and how well it works.
Cleveland, OhioAges 18 years+ - NCT07003295RecruitingPhase 2
Glofitamab for mantle cell lymphoma that returned after CAR-T
This trial tests a new drug, glofitamab, for mantle cell lymphoma that came back or didn’t respond after CAR-T cell therapy. It aims to see if glofitamab can shrink or control the lymphoma.
Cleveland, OhioAges 18 years+ - NCT06742996RecruitingPhase 3
Sonrotoclax plus zanubrutinib for relapsed mantle cell lymphoma
This trial tests a new combination of two targeted therapies for people with mantle cell lymphoma that has come back or hasn't responded to prior treatment. It aims to see if adding sonrotoclax to zanubrutinib works better than zanubrutinib alone.
Cleveland, OhioAges 18 years+ - NCT06724237RecruitingPhase 3
High-dose chemo and stem cell transplant for T-cell lymphoma patients in remission
This trial tests whether high-dose chemotherapy followed by a stem cell transplant using your own cells can help people with certain types of peripheral T-cell lymphoma live longer. You would qualify if you have already finished your first round of chemotherapy and are in complete remission.
Athens, OhioAges 18–75 - NCT06649812RecruitingPhase 2
Testing a combination targeted therapy (ViPOR) for aggressive B-cell lymphoma
This trial tests a new combination of targeted drugs called ViPOR for people with aggressive B-cell lymphoma that has come back or not responded to previous treatment. The goal is to see if this treatment can help when standard therapies haven't worked.
Canton, OhioAges 18 years+ - NCT06564038RecruitingPhase 1/Phase 2
Study of AZD0486 alone or with other drugs for B-cell cancers
This trial tests a new drug called AZD0486, alone or with other medicines, for people with certain types of B-cell cancers that have come back or not responded to treatment. The goal is to see how safe and effective it is.
Columbus, OhioAges 18 years+ - NCT06561048RecruitingPhase 3
Soquelitinib vs standard care for relapsed or refractory T-cell lymphoma
This trial compares a new drug, soquelitinib, with standard treatments for peripheral T-cell lymphoma that has come back or not responded to previous therapy. It may help people who have had one to three prior treatments and are looking for a new option.
Columbus, OhioAges 18 years+ - NCT06534060RecruitingPhase 2
Testing MB-105 for CD5 positive T-cell lymphoma
This trial tests a new treatment called MB-105 for people with a type of T-cell lymphoma that has come back or not responded to other treatments. MB-105 is designed to target and attack cancer cells that have a specific marker called CD5 on their surface.
Cleveland, OhioAges 18 years+ - NCT06536049RecruitingPhase 1/Phase 2
Epcoritamab plus ibrutinib for relapsed or refractory aggressive B-cell lymphoma
This trial tests a combination of two drugs – epcoritamab (a type of immunotherapy that helps your immune system attack lymphoma cells) and ibrutinib (a targeted pill that blocks signals that help cancer grow). It is for people with aggressive B-cell lymphoma that has come back or not responded to at least 2 prior treatments.
Columbus, OhioAges 18 years+ - NCT06514794RecruitingPhase 2
A study of a new cell therapy for T-cell acute lymphoblastic leukemia and lymphoma
This trial tests an investigational cell therapy that uses donated immune cells to find and destroy cancer cells in patients with T-cell acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LBL) that has come back or not responded to treatment. The goal is to see if this therapy can help achieve remission for these patients.
Cincinnati, OhioAges 6 months+ - NCT06393738RecruitingPhase 1
ARV-393 for relapsed or refractory non-Hodgkin lymphoma
This study tests a new oral medication (ARV-393) for people with certain types of non-Hodgkin lymphoma that have returned or not responded to previous treatments. The drug is designed to target a protein inside cancer cells to make them stop growing and die.
Cleveland, OhioAges 18 years+ - NCT06343311RecruitingPhase 1/Phase 2
T-cell therapy for adults with relapsed or refractory B-cell lymphoma
This trial tests a new T-cell therapy (EB103) for people with B-cell non-Hodgkin's lymphoma that has come back or stopped responding to treatment. It aims to see if the therapy is safe and effective.
Cleveland, OhioAges 18 years+ - NCT06131801Recruiting
Crushed venetoclax tablet solution study for blood cancers
This study checks how the body handles venetoclax when it's given as a liquid made from crushed tablets. It's for children and young adults with blood cancers who already take venetoclax crushed or through a feeding tube.
Cincinnati, OhioAges birth–38 years - NCT06015880RecruitingPhase 1
Combination drug therapy for relapsed or resistant large B-cell lymphoma
This trial tests a combination of three drugs (mosunetuzumab, polatuzumab vedotin, and lenalidomide) for people with diffuse large B-cell lymphoma (a type of blood cancer) that has come back or not responded to previous treatment. The goal is to see if this combination is safe and effective.
Cleveland, OhioAges 18 years+ - NCT06022029RecruitingPhase 1
Study of injected ONM-501 alone or with cemiplimab for advanced cancers
This trial tests an injected study drug (ONM-501) alone or with another drug (cemiplimab) for people with advanced solid tumors or lymphomas that haven't responded to other treatments. It aims to find a safe dose and see if the combination helps shrink or control the cancer.
Canton, OhioAges 18 years+ - NCT05978141Recruiting
T-cell lymphoma registry study
This study creates a registry for people with certain T-cell or NK-cell lymphomas. It collects health information and tumor samples to learn more about these diseases and improve future treatments.
Columbus, OhioAges Any age - NCT05755087RecruitingPhase 1
Tegavivint for relapsed or hard-to-treat lymphoma patients
This Phase 1 trial tests tegavivint, a new investigational medicine, for certain types of aggressive B-cell lymphoma that have come back or did not respond to prior treatment. It may help shrink the lymphoma and learn how safe and effective the drug is in this setting.
Columbus, OhioAges 18 years+
T-cell Lymphoma trials by city in Ohio
Where these studies are running in Ohio
Institutions with a site for the recruiting t-cell lymphoma studies listed above.
- The Ohio State University · 9 studies
- Case Western Reserve University · 3 studies
- Cincinnati Children's Hospital Medical Center · 3 studies
- Cleveland Clinic · 2 studies
- University Hospitals Cleveland Medical Center · 2 studies
- Aultman Health Foundation
- Cleveland Clinic Foundation
- Cleveland Clinical Taussig Cancer Center
What taking part in a t-cell lymphoma study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
T-cell Lymphoma trials in other states
Common questions
- Are there t-cell lymphoma clinical trials in Ohio?
- Yes. We're currently tracking 41 recruiting t-cell lymphoma studies with a site in Ohio, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a t-cell lymphoma study in Ohio?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Ohio to take part?
- Not necessarily. These studies have a site in Ohio, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a t-cell lymphoma trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New t-cell lymphoma studies open in Ohio regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.